Lexington Biosciences Inc. (LXGTF)

[PennyMaster]

$LXGTF Wearable Tech Could Disrupt An Industry Worth Billions

Biometrics, once thought of as futuristic is becoming increasingly popular different aspects of daily life and for investors as well.

THE BIOMETRIC MARKET IS EXPECTED TO GROW AT A CAGR OF 29.3% TO REACH USD $49.33 BILLION BY 2022.



This growth will be driven by increased use of biotech in government, financial, and healthcare sectors. While companies typically try to appeal to different markets, there have been major innovations in the healthcare industry for wearable medical devices.
Big name companies like Apple, Alphabet the parent company of Google, and International Business Machines Corp. are making their way into the healthcare sector as well. With their expertise and ample resources it can change the industry completely in a good way.

The potential for growth in this market right now is remarkable. The wearablemarketsandmarkets medical device market is projected to reach $12.14 billion by 2021 from $5.31 billion in 2016, with a CAGR of 18.0% according to MarketsandMarkets research. The growth is driven by increased health awareness, technological advancements in medical devices, and increased smartphone health apps that are compatible with these wearable devices.

A study by ITOnline shows that two-thirds of Americans already favor digital health management rather than physical. The study also shown that 79 percent of Americans stated they would utilize a wearable device to manage their health. About 45% wanted to track symptoms while 43% percent wanted it to manage a specific health condition.

The healthcare model is evolving and wearables correlate significantly to this new model. Care is no longer visiting a doctor or medical center. Care is coming to you the patient, wherever you are with your smartphone.

WHAT’S BETTER THAN THAT?

Lexington Biosciences (LXGTF) is a developmental stage medical device company that is developing a new non-invasive diagnostic device that can measure and monitor cardiovascular health.

Before, this development the only way to measure this was using ultrasound and other complex technologies. Currently, the company is in the final stages of releasing the developed product for clinical studies.

According to the World Health Organization (WHO) cardiovascular disease and stroke are the primary cause of death worldwide. In the United States alone, approximately 1.5 million people annually suffer from heart attacks and more than 250,000 people die within the first hour of an attack. Sadly, as many as 50% of people do not show signs or symptoms until it is too late.

Lexington Biosciences (LXGTF) is revolutionizing not only the healthcare market but the Biometric market with a product first in class to monitor vascular health and detect cardiovascular disease even at a premature stage. With simple and effective technology, this product can save a life.

The (LXGTF) product, HEARTSENTRY, quantifies the function of the endothelium or the cells that line the arteries. You can envision endothelium as a defense against plaque from developing inside the artery wall.

The cells also create elements that prevent blood clots from developing in the vessel. These cells are vital to the prevention of atherosclerosis, the hardening and narrowing of the arteries and the usual culprit for heart attacks and stroke.

With the familiar design to that of a blood pressure machine, this life saving technology has an ease of use while adding modern day technology. HEARTSENTRY utilizes Bluetooth and Cloud technology to provide accurate reporting of an individual’s cardiovascular health to directly target the unmet medical need for early detection.

http://techstockinsider.com/the-wearable-tech-thats-disrupting-an-industry-worth-billions/